MAGE-A Antigens and Cancer Immunotherapy.
MAGE-A antigens are expressed in a variety of cancers of diverse histological origin and germinal cells. Due to their relatively high tumor specificity, they represent attractive targets for active specific and adoptive cancer immunotherapies. Here, we (i) review past and ongoing clinical studies targeting these antigens, (ii) analyze advantages and disadvantages of different therapeutic approaches, and (iii) discuss possible improvements in MAGE-A-specific immunotherapies.
Oncology Surgery, Department of Biomedicine, University Hospital of Basel , Basel , Switzerland.
Paul
P
Zajac
Oncology Surgery, Department of Biomedicine, University Hospital of Basel , Basel , Switzerland.
Elke
E
Schultz-Thater
Department of Pathology, University Hospital of Basel , Basel , Switzerland.
Luigi
L
Tornillo
Oncology Surgery, Department of Biomedicine, University Hospital of Basel , Basel , Switzerland.
Charlotte
C
Sadowski
Oncology Surgery, Department of Biomedicine, University Hospital of Basel , Basel , Switzerland.
Emanuele
E
Trella
Oncology Surgery, Department of Biomedicine, University Hospital of Basel , Basel , Switzerland.
Chantal
C
Mengus
Cancer Immunotherapy, Department of Biomedicine, University Hospital of Basel , Basel , Switzerland.
Giandomenica
G
Iezzi
Oncology Surgery, Department of Biomedicine, University Hospital of Basel , Basel , Switzerland.
Giulio C
GC
Spagnoli
MAGE-A; adoptive immunotherapy; cancer immunotherapy; cancer–testis antigens; clinical trials